Aviance Capital Management’s AstraZeneca AZN Stock Holding History

Aviance Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$2K	Sell	30 -61,526	-100%	-$4.85M	﹤0.01%	213
2018 Q4	$4.68M	Buy	61,556 +57,563	+1,442%	+$4.5M	0.66%	47
2018 Q3	$316K	Buy	+3,993	New	+$302K	0.03%	137
2018 Q2	–	Sell	-41	Closed	-$3K	–	207
2018 Q1	$3K	Buy	+41	New	+$2.84K	﹤0.01%	250
2017 Q4	–	Sell	-51	Closed	-$3K	–	269
2017 Q3	$3K	Buy	51 +3	+6%	+$190	﹤0.01%	291
2017 Q2	$3K	Buy	+48	New	+$3.13K	﹤0.01%	313
2016 Q4	–	Sell	-198,762	Closed	-$13.1M	–	202
2016 Q3	$13.1M	Buy	+198,762	New	+$13M	0.36%	76
2014 Q2	–	Sell	-88,226	Closed	-$5.72M	–	289
2014 Q1	$5.72M	Buy	88,226 +76,983	+685%	+$4.97M	0.29%	60
2013 Q4	$667K	Sell	11,243 -941	-8%	-$51.1K	0.36%	60
2013 Q3	$633K	Sell	12,184 -26,411	-68%	-$1.33M	0.37%	58
2013 Q2	$1.83M	Buy	+38,595	New	+$1.97M	1%	33

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aviance Capital Management's AZN Position: Q1 2019 in Review

Aviance Capital Management reduced its AstraZeneca (AZN) stake by 100% in Q1 2019, selling an estimated $4.85M and leaving 30 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #213.

Aviance Capital Management first reported a position in AZN in Q2 2013 and has held it in 11 quarters since. The position peaked at $13.1M in Q3 2016. 560 funds tracked by Wall St. Rank hold AZN as of Q1 2019.

Aviance Capital Management held 30 shares of AstraZeneca worth $2K as of Q1 2019.
Aviance Capital Management sold 61,526 AstraZeneca shares in Q1 2019, an estimated $4.85M.
AstraZeneca made up ﹤0.01% of Aviance Capital Management's portfolio in Q1 2019, its #213 holding.
Aviance Capital Management first reported a position in AstraZeneca in Q2 2013 and has held it in 11 quarters since.
Aviance Capital Management's AstraZeneca position peaked at $13.1M in Q3 2016.
560 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2019.

Based on Aviance Capital Management's 13F filing for Q1 2019, filed 15 May 2019.